More News

16 May 2020

LegoChem Biosciences and Iksuda Enter Licensing Agreement for Antibody Drug Conjugate Program

14 May 2020

Recursion Enters Into Global Licensing Agreement with Takeda to Develop TAK-733 in Hereditary Cancer Syndrome

14 May 2020

Skyhawk Therapeutics Announces Expansion of its Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modulate RNA…

13 May 2020

Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy, a Leading Cause of Blindness Worldwide

12 May 2020

Neurocrine Biosciences exercises option to license Idorsia’s novel treatment for rare pediatric epilepsy

12 May 2020

Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration

8 May 2020

ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration

7 May 2020

PTC Therapeutics to Acquire Censa Pharmaceuticals

7 May 2020

Mediolanum Farmaceutici Acquires the French Company ElsaLys Biotech to Develop Next Generation Immuno-oncology Therapies

6 May 2020

BERG Forms Research Collaboration With Boehringer Ingelheim To Identify Candidate Biomarkers For A Group Of Inflammatory Conditions

6 May 2020

Magenta Therapeutics and AVROBIO Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies

6 May 2020

Santhera Signs Agreements in Gene Therapy Research for Congenital Muscular Dystrophy with Rutgers University

5 May 2020

Alexion to Acquire Portola

4 May 2020

Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

4 May 2020

Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark

4 May 2020

BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies

29 April 2020

resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology

27 April 2020

Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies

27 April 2020

Merck and Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers

24 April 2020

ProThera Biologics and Takeda Enter Global Licensing Agreement to Develop Novel Plasma-Derived Therapy Based on Inter-alpha Inhibitor Proteins (IAIP)

23 April 2020

EpimAb Biotherapeutics and QIMR Berghofer Medical Research Institute Announce Research Collaboration and License Agreement on Novel Bispecific Target Combinations

22 April 2020

Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138

22 April 2020

Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology

21 April 2020

Mogrify and Sangamo Announce Collaboration and Exclusive License Agreement for Mogrify’s iPSC- and ESC-Derived Regulatory T Cells

21 April 2020

Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan

20 April 2020

COVID-19: 155 drugs and 79 vaccines under development worldwide

17 April 2020

Kubota Vision Announces Signing of Open Innovation Agreement with LEO Pharma A/S to Screen Novel VAP-1 Inhibitor Compounds for Inflammatory Skin Diseases

17 April 2020

LegoChem Biosciences and Iksuda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates

16 April 2020

Galapagos and Ryvu Announce Research Collaboration

15 April 2020

Y-mAbs enters into Worldwide Exclusive License Agreement for SADA Technology – a Novel Radioimmunotherapy Platform

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Report Package: Claudin 18.2-Targeted Immunotherapeutics

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

PD-1 Agonists Pipeline Review

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

CD40 Agonists & CD40/L Antagonists Pipeline Review

c-Met-Targeted Antibody Therapy Pipeline Review

CD73 Inhibitor Pipeline Review